APA

van Dyck C. H., Sadowsky C., Le Prince Leterme G., Booth K., Peng Y., Marek K., Ketter N., Liu E., Wyman B. T., Jackson N., Slomkowski M. & Ryan J. M. (2016). Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study. : The journal of prevention of Alzheimer's disease.

Chicago

van Dyck C H, Sadowsky C, Le Prince Leterme G, Booth K, Peng Y, Marek K, Ketter N, Liu E, Wyman B T, Jackson N, Slomkowski M and Ryan J M. 2016. Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study. : The journal of prevention of Alzheimer's disease.

Harvard

van Dyck C. H., Sadowsky C., Le Prince Leterme G., Booth K., Peng Y., Marek K., Ketter N., Liu E., Wyman B. T., Jackson N., Slomkowski M. and Ryan J. M. (2016). Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study. : The journal of prevention of Alzheimer's disease.

MLA

van Dyck C H, Sadowsky C, Le Prince Leterme G, Booth K, Peng Y, Marek K, Ketter N, Liu E, Wyman B T, Jackson N, Slomkowski M and Ryan J M. Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study. : The journal of prevention of Alzheimer's disease. 2016.